Rain Oncology IncNASDAQ RAIN Stock Report

Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company is headquartered in Newark California, California and currently employs 63 full-time employees. The company went IPO on 2021-04-23. The firm is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.